-
1
-
-
9944234591
-
Measuring treatment impact: A review of patient-reported outcomes and other efficacy endpoints in approved product labels
-
Wilke RJ, Burke LB, Erickson P: Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004, 25: 535-552.
-
(2004)
Control Clin. Trials
, vol.25
, pp. 535-552
-
-
Wilke, R.J.1
Burke, L.B.2
Erickson, P.3
-
2
-
-
0141506945
-
PRO Harmonization Group: Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the Patient-reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001
-
Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M; PRO Harmonization Group: Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003, 6: 522-531.
-
(2003)
Value Health
, vol.6
, pp. 522-531
-
-
Acquadro, C.1
Berzon, R.2
Dubois, D.3
Leidy, N.K.4
Marquis, P.5
Revicki, D.6
Rothman, M.7
-
3
-
-
16344377314
-
Assessing Treatment Impact Using Patient-Reported Outcomes (PROs): Challenges in Study Design, Conduct and Analysis
-
The ERIQA Group: Meeting Report (Paris, May 10-11, 2004). Special Issue
-
The ERIQA Group: Assessing Treatment Impact Using Patient-Reported Outcomes (PROs): Challenges in Study Design, Conduct and Analysis. Meeting Report (Paris, May 10-11, 2004). Patient-Reported Outcomes Newsletter 2005, Special Issue 3: 1-16.
-
(2005)
Patient-Reported Outcomes Newsletter
, vol.3
, pp. 1-16
-
-
-
4
-
-
0037310623
-
Quality of life and objective disease criteria in patients with intermittent claudication in general practice
-
Muller-Buhl U, Engeser P, Klimm HD, Wiesemann A: Quality of life and objective disease criteria in patients with intermittent claudication in general practice. Fam Pract 2003, 20: 36-40.
-
(2003)
Fam. Pract.
, vol.20
, pp. 36-40
-
-
Muller-Buhl, U.1
Engeser, P.2
Klimm, H.D.3
Wiesemann, A.4
-
5
-
-
0041346513
-
Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
-
Bolling-Sternevald E, Lauritsen K, Talley NJ, Junghard O, Glise H: Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 2003,18: 117-124.
-
(2003)
Aliment. Pharmacol. Ther.
, vol.18
, pp. 117-124
-
-
Bolling-Sternevald, E.1
Lauritsen, K.2
Talley, N.J.3
Junghard, O.4
Glise, H.5
-
6
-
-
0037842153
-
Eastern Cooperative Oncology Group: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592
-
Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH; Eastern Cooperative Oncology Group: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003, 21 1536-1543.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 1536-1543
-
-
Eton, D.T.1
Fairclough, D.L.2
Cella, D.3
Yount, S.E.4
Bonomi, P.5
Johnson, D.H.6
-
7
-
-
0036185590
-
Patient Reported Outcomes and Regulatory Issues: The Example of Health-related Quality of Life - A European Guidance Document for the Improved Integration of HRQL Assessment in the Drug Regulatory Process
-
Chassany O, Sagnier P, Marquis P, Fulleton S, Aaronson N: Patient Reported Outcomes and Regulatory Issues: the Example of Health-related Quality of Life - A European Guidance Document for the Improved Integration of HRQL Assessment in the Drug Regulatory Process Drug Inf J 2002, 36: 209-238.
-
(2002)
Drug Inf. J.
, vol.36
, pp. 209-238
-
-
Chassany, O.1
Sagnier, P.2
Marquis, P.3
Fulleton, S.4
Aaronson, N.5
-
8
-
-
0000078123
-
Recommendations for evaluating the validity of quality of life claims for labeling and promotion
-
Revicki DA, Leidy NK, Geneste B: Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999, 2:113-127.
-
(1999)
Value Health
, vol.2
, pp. 113-127
-
-
Revicki, D.A.1
Leidy, N.K.2
Geneste, B.3
|